Background:Venous ulcer represents the most advanced stage of chronic venous insufficiency.It is an important public health problem and has a significant impact on patients’quality of life due to chronic pain,inabili...Background:Venous ulcer represents the most advanced stage of chronic venous insufficiency.It is an important public health problem and has a significant impact on patients’quality of life due to chronic pain,inability to work,need for hospitalization and frequent outpatient follow-up.Objective:We investigated the treatment benefits of far-infrared ceramic(cFIR),in a 90-day study of lower limb venous ulcers and looked at ulcer healing scores,quality of life,serum bio-markers of oxidative stress and antioxidant defense enzymes.Design,setting,participants and interventions:This is a randomized double-blind placebo-controlled study conducted in the Vascular Surgery Service of a hospital located in the northwest region of the State of Rio Grande do Sul,Brazil.We included patients with lower limb venous ulcers who were randomized to use either a bioceramics wrap or a placebo wrap for 90 days.Main outcome measures:The following evaluations were conducted at baseline and after 15,30,60 and90 days:ulcer healing score,quality of life,and serum markers of oxidative stress and antioxidant enzyme activity.Results:Patients(n=24)with lower limb venous ulcers were randomized into two treatment groups.cFIR decreased the ulcer size on day 30(P=0.042)and 90(P=0.034)and the total ulcer healing scale scores on day 30(P=0.049)and 90(P=0.02)of the treatment,when compared to baseline.Additionally,cFIR improved tissue type(epithelial tissue)on day 60(P=0.022)when compared to baseline evaluation.Conclusion:cFIR clinically improved ulcer healing in patients with lower limb venous ulcers.Trial registration:RBR-8c7xzn on ReBEC.展开更多
Objective: The present study aimed to evaluate the analgesic and anti-inflammatory effects of far infrared-emitting ceramics (cFIRs) in a model of persistent inflammatory hyperalgesia and to elucidate the possible ...Objective: The present study aimed to evaluate the analgesic and anti-inflammatory effects of far infrared-emitting ceramics (cFIRs) in a model of persistent inflammatory hyperalgesia and to elucidate the possible mechanisms of these effects. Methods: Mice were injected with complete Freund's adjuvant (CFA) and treated with cFIRs via place- ment on a pad impregnated with cFIRs on the bottom of the housing unit for different periods of time. Mice underwent mechanical hyperalgesia and edema assessments, and tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-10 levels were measured. Twenty-four hours after CFA injection and 30 min before cFIR treatment, mice were pretreated with a nonselective adenosinergic antagonist, caffeine, the selective adenosine receptor A antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), the selective cannabinoid receptor type 1 antagonist, AM281, the selective cannabinoid receptor type 2 antagonist, AM630, or the nonselective opioid receptor antagonist, naloxone, and mechanical hyperalge- sia was assessed. Results: cFIRs statistically (P 〈 0.05) decreased CFA-induced mechanical hyperalgesia (82.86 ±5.21)% in control group vs (56.67±9.54)% in cFIR group) and edema ((1699.0 ± 77.8) gm in control group vs (988.7±107.6) gm in cFIR group), cFIRs statistically (P 〈 0.05) reduced TNF-α (0.478± 0.072) pg/mg of protein in control group vs (0.273 ±0.055) pg/mg of protein in cFIR group) and IL-113 ((95.81 ± 3.95) pg/mg of protein in control group vs (80.61 ±4.71)pg/mg of protein in cFIR group) levels and statistically (P〈 0.05) increased IL-10 ((18.32 ±0.78) pg/mg of protein in control group vs (25.89 ±1.23) pg/mg of protein in cFIR group) levels in post-CFA-injected paws. Peripheral pre-administration of inhibitory neuroreceptor antagonists (caffeine, DPCPX, AM281, AM630 and naloxone) prevented the analgesic effects of cF1Rs (P 〈 0.05).Conclusion: These data provide additional support for the use of cFIRs in the treatment of painful inflam- matory conditions and contribute to our understanding of the neurobiological mechanisms of the ther- apeutic effects of cFIRs.展开更多
基金supported by the National Council for Scientific and Technological Development(CNPq,grant number476454/2013-1)the Research Support and Innovation Foundation of the State of Santa Catarina(FAPESC,grant numbers 3414/2012and FAPESC-2019TR73)+2 种基金the Coordination for the Improvement of Higher Education Personnel(CAPES)the UNISUL and UNIJUI Scientific Initiation Program(PUIC)supported by research fellowships from CNPq(309407/2017-6).
文摘Background:Venous ulcer represents the most advanced stage of chronic venous insufficiency.It is an important public health problem and has a significant impact on patients’quality of life due to chronic pain,inability to work,need for hospitalization and frequent outpatient follow-up.Objective:We investigated the treatment benefits of far-infrared ceramic(cFIR),in a 90-day study of lower limb venous ulcers and looked at ulcer healing scores,quality of life,serum bio-markers of oxidative stress and antioxidant defense enzymes.Design,setting,participants and interventions:This is a randomized double-blind placebo-controlled study conducted in the Vascular Surgery Service of a hospital located in the northwest region of the State of Rio Grande do Sul,Brazil.We included patients with lower limb venous ulcers who were randomized to use either a bioceramics wrap or a placebo wrap for 90 days.Main outcome measures:The following evaluations were conducted at baseline and after 15,30,60 and90 days:ulcer healing score,quality of life,and serum markers of oxidative stress and antioxidant enzyme activity.Results:Patients(n=24)with lower limb venous ulcers were randomized into two treatment groups.cFIR decreased the ulcer size on day 30(P=0.042)and 90(P=0.034)and the total ulcer healing scale scores on day 30(P=0.049)and 90(P=0.02)of the treatment,when compared to baseline.Additionally,cFIR improved tissue type(epithelial tissue)on day 60(P=0.022)when compared to baseline evaluation.Conclusion:cFIR clinically improved ulcer healing in patients with lower limb venous ulcers.Trial registration:RBR-8c7xzn on ReBEC.
基金supported by grants from the National Council of Scientific and Technological Development(CNPq)grant#14/2013the Santa Catarina State Foundation in Support of Research and Innovation(FAPESC)grant#04/2012+1 种基金the Coordination of Higher Education Personnel Improvement(CAPES)the UNISUL Scientific Initiation Program(PUIC),Brazil
文摘Objective: The present study aimed to evaluate the analgesic and anti-inflammatory effects of far infrared-emitting ceramics (cFIRs) in a model of persistent inflammatory hyperalgesia and to elucidate the possible mechanisms of these effects. Methods: Mice were injected with complete Freund's adjuvant (CFA) and treated with cFIRs via place- ment on a pad impregnated with cFIRs on the bottom of the housing unit for different periods of time. Mice underwent mechanical hyperalgesia and edema assessments, and tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and IL-10 levels were measured. Twenty-four hours after CFA injection and 30 min before cFIR treatment, mice were pretreated with a nonselective adenosinergic antagonist, caffeine, the selective adenosine receptor A antagonist, 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), the selective cannabinoid receptor type 1 antagonist, AM281, the selective cannabinoid receptor type 2 antagonist, AM630, or the nonselective opioid receptor antagonist, naloxone, and mechanical hyperalge- sia was assessed. Results: cFIRs statistically (P 〈 0.05) decreased CFA-induced mechanical hyperalgesia (82.86 ±5.21)% in control group vs (56.67±9.54)% in cFIR group) and edema ((1699.0 ± 77.8) gm in control group vs (988.7±107.6) gm in cFIR group), cFIRs statistically (P 〈 0.05) reduced TNF-α (0.478± 0.072) pg/mg of protein in control group vs (0.273 ±0.055) pg/mg of protein in cFIR group) and IL-113 ((95.81 ± 3.95) pg/mg of protein in control group vs (80.61 ±4.71)pg/mg of protein in cFIR group) levels and statistically (P〈 0.05) increased IL-10 ((18.32 ±0.78) pg/mg of protein in control group vs (25.89 ±1.23) pg/mg of protein in cFIR group) levels in post-CFA-injected paws. Peripheral pre-administration of inhibitory neuroreceptor antagonists (caffeine, DPCPX, AM281, AM630 and naloxone) prevented the analgesic effects of cF1Rs (P 〈 0.05).Conclusion: These data provide additional support for the use of cFIRs in the treatment of painful inflam- matory conditions and contribute to our understanding of the neurobiological mechanisms of the ther- apeutic effects of cFIRs.